Phase II Study for Robot Assisted Distal Gastrectomy
Phase 2
- Conditions
- Early Gastric Cancer
- Interventions
- Device: Robot assisted distal gastrectomy (DaVinci)
- Registration Number
- NCT01504997
- Lead Sponsor
- Shizuoka Cancer Center
- Brief Summary
The aim of this study is to clarify safety of robot assisted distal gastrectomy with lymph node dissection in patients with stage Ia early gastric cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 23
Inclusion Criteria
- Biopsy specimen from the primary lesion shows adenocarcinoma
- Diagnosed as Stage IA early gastric cancer according to the preoperative esophagogastroduodenoscopy and computer tomography
- Endoscopic submucosal dissection is not indicated
- Tumor was located within lower two thirds of stomach
- Not having duodenal invasion
- Eastern clinical oncology group performance status is 0 or 1
- Body mass index is lower than 30
- No prior laparotomy
- No prior chemotherapy or radiation including those for other cancers
- Fulfil all following conditions WBC > 3,000/mm3 Plt > 100,000/mm3 AST < 100 IU/L ALT < 100IU/L T.Bil < 2.0 g/dl Cre < 1.5mg/dl
Exclusion Criteria
- Having other active cancers
- Possibly pregnant, or breast feeding woman
- with psychiatric disorder
- Receiving steroids
- With Acute myocardial infarction in 6 months or with unstable angina
- With uncontrolled hypertension
- With uncontrolled diabetes mellitus
- With pulmonary disease which require continuous oxygen therapy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Robot assisted distal gastrectomy Robot assisted distal gastrectomy (DaVinci) patients who received robot assisted distal gastrectomy
- Primary Outcome Measures
Name Time Method The Incidence of Post-operative Intra-abdominal Infectious Complications Participants will be followed for the duration of hospital stay, an expected average of 10 days
- Secondary Outcome Measures
Name Time Method Relapse Free Survival 5 years Incidence of Adverse Events Participants will be followed for the duration of hospital stay, an expected average of 10 days Overall Survival 5 years Completion Rate of Robot Assisted Surgery During the surgery, an expected average of 5 hours
Trial Locations
- Locations (1)
Shizuoka Cancer Center
🇯🇵Shizuoka, Japan